Results 121 to 130 of about 31,348 (237)
A case of Langerhans' cell histiocytosis following Hodgkin's disease. [PDF]
Li X, Deng QI, Li YM.
europepmc +1 more source
New analysis from 15 years of Indonesian Demographic Health Survey Data has identified a shift from home birth to hospital birth. However, 65% of women who gave birth in hospital had no risk factors, while 13% of women who gave birth at home did report pregnancy‐related risk factors.
Kai Hodgkin +2 more
wiley +1 more source
Prognostic Factors of Hodgkin's Disease Recurrence: An Experience From a Tertiary Academic Center in Iran. [PDF]
Seifi S +3 more
europepmc +1 more source
C, Worster-Drought, T R, Hill
openaire +2 more sources
Summary Diffuse large B‐cell lymphoma (DLBCL) is the most common aggressive non‐Hodgkin lymphoma and is characterized by substantial heterogeneity. This study aimed to develop a liquid–liquid phase separation (LLPS)‐related prognostic model to improve risk stratification.
Zhen‐Zhong Zhou +11 more
wiley +1 more source
Clinical periodontal diagnosis
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi +5 more
wiley +1 more source
Summary Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL.
L. Ceriani +10 more
wiley +1 more source
Omental Cake in Non-Hodgkin's Disease: 18F-FDG PET-CT Findings. [PDF]
Otmani M +4 more
europepmc +1 more source
Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease. [PDF]
Lautenschlaeger S +11 more
europepmc +1 more source
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo +14 more
wiley +1 more source

